Author:
Pandey Avinash,Dutt Sarjana,Singh Anjana,Kumar Amit,Singh Shivkant
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Authors’ reply to Pai and Varghese, and Kenkre et al.;Cancer Research, Statistics, and Treatment;2024-01
2. Gefitinib triumphs: Long-term advantages over chemotherapy in the treatment of EGFR mutant lung cancer;Cancer Research, Statistics, and Treatment;2024-01
3. A personalized approach to the management of rare genetic aberrations in oncology: A letter citing the EGFR exon 18 mutation molecular tumor board report;Cancer Research, Statistics, and Treatment;2024-01
4. Testing modalities for ALK-driven lung cancer: A narrative review;Cancer Research, Statistics, and Treatment;2023
5. ROS1-positive lung cancer: Facts to be remembered;Cancer Research, Statistics, and Treatment;2023